- Home
- ASPC vs ASMB Comparison
ASPC vs ASMB Comparison
Compare ASPC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPC
- ASMB
- Stock Information
- Founded
- ASPC 2024
- ASMB 2005
- Country
- ASPC Hong Kong
- ASMB United States
- Employees
- ASPC N/A
- ASMB N/A
- Industry
- ASPC
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- ASPC
- ASMB Health Care
- Exchange
- ASPC Nasdaq
- ASMB Nasdaq
- Market Cap
- ASPC 80.9M
- ASMB 76.9M
- IPO Year
- ASPC 2024
- ASMB 2010
- Fundamental
- Price
- ASPC $10.14
- ASMB $14.13
- Analyst Decision
- ASPC
- ASMB Strong Buy
- Analyst Count
- ASPC 0
- ASMB 3
- Target Price
- ASPC N/A
- ASMB $33.00
- AVG Volume (30 Days)
- ASPC 9.6K
- ASMB 26.6K
- Earning Date
- ASPC 01-01-0001
- ASMB 05-12-2025
- Dividend Yield
- ASPC N/A
- ASMB N/A
- EPS Growth
- ASPC N/A
- ASMB N/A
- EPS
- ASPC N/A
- ASMB N/A
- Revenue
- ASPC N/A
- ASMB $28,520,000.00
- Revenue This Year
- ASPC N/A
- ASMB $10.82
- Revenue Next Year
- ASPC N/A
- ASMB N/A
- P/E Ratio
- ASPC N/A
- ASMB N/A
- Revenue Growth
- ASPC N/A
- ASMB 298.16
- 52 Week Low
- ASPC $9.95
- ASMB $7.75
- 52 Week High
- ASPC $10.51
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- ASPC N/A
- ASMB 78.03
- Support Level
- ASPC N/A
- ASMB $9.82
- Resistance Level
- ASPC N/A
- ASMB $10.76
- Average True Range (ATR)
- ASPC 0.00
- ASMB 0.62
- MACD
- ASPC 0.00
- ASMB 0.51
- Stochastic Oscillator
- ASPC 0.00
- ASMB 87.00
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.